Welcome to our dedicated page for Amicus Therapeut news (Ticker: FOLD), a resource for investors and traders seeking the latest updates and insights on Amicus Therapeut stock.
News for Amicus Therapeutics, Inc. (NASDAQ: FOLD) centers on its role as a global, patient-dedicated biotechnology company focused on rare diseases, along with updates on its commercial therapies and corporate developments. Company press releases describe Amicus as developing and commercializing medicines for Fabry disease and late-onset Pompe disease, as well as advancing programs in focal segmental glomerulosclerosis (FSGS).
Investors following FOLD news will see regular quarterly financial results, where Amicus reports net product revenues for Galafold (migalastat) and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat). These updates often discuss revenue growth at constant exchange rates, progress toward profitability measures and cash position, giving context for how its rare disease portfolio is performing.
Clinical and medical news items highlight data from the Phase 3 PROPEL study and its open-label extension in adults with late-onset Pompe disease, as well as new analyses and publications in journals such as Muscle and Nerve. These releases summarize outcomes related to six-minute walk distance, pulmonary function, muscle strength, biomarkers and patient-reported measures, and they provide details on long-term safety and efficacy observations for Pombiliti + Opfolda.
Regulatory and market access announcements include approvals and reimbursement milestones for Pombiliti + Opfolda in regions such as Japan, the U.S., European Union, United Kingdom, Canada, Australia and Switzerland. News also covers conference presentations at major healthcare and investor events, where Amicus discusses its rare disease programs and business outlook.
A significant corporate headline is the December 19, 2025 announcement that BioMarin Pharmaceutical Inc. entered into a definitive agreement to acquire Amicus in an all-cash transaction. Updates related to this proposed acquisition, alongside ongoing financial and clinical disclosures, make the FOLD news feed a key source of information on the company’s evolution in the rare disease biotechnology space.
Amicus Therapeutics (Nasdaq: FOLD) announces that CEO John F. Crowley will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on June 10, 2020, at 8:00 a.m. ET. This event will take place virtually, allowing interested parties to access a live audio webcast via the company's Investor Relations page. Amicus Therapeutics focuses on developing innovative medicines for rare metabolic diseases, furthering its commitment to patients through a robust pipeline of advanced therapies. For details, visit www.amicusrx.com.
Amicus Therapeutics (Nasdaq: FOLD) announced the acceptance of multiple abstracts for the American Society of Gene & Cell Therapy 23rd Annual Meeting on May 12-15, 2020. The presentation includes preclinical data from the Pompe gene therapy program, alongside CLN6 and CLN8 Batten disease programs. The oral presentation is scheduled for May 14, showcasing a study on gene therapy for Pompe disease. Poster presentations will cover data on CLN6 and CLN8 Batten diseases. Pompe disease affects 5,000-10,000 people globally and is characterized by severe muscle weakness.
Amicus Therapeutics (Nasdaq: FOLD) announced acceptance of several abstracts for the American Society of Gene & Cell Therapy 23rd Annual Meeting held virtually from May 12-15, 2020. The highlights include:
- Oral Presentation: Preclinical data on Pompe gene therapy on May 14, 2020.
- Poster Presentations: Research on CLN6 Batten disease on May 12 and CLN8 Batten disease on May 13.
POMPE and Batten diseases are rare genetic disorders affecting muscle and neurological function, respectively.